[1]孙伏清,林永芳,周 密,等.他汀强化预处理对PCI介导CEMPAS的防治效果观察[J].福建医药杂志,2021,43(02):27-30.
　SUN Fuqing,LIN Yongfang,ZHOU Mi,et al.Statin pretreatment and intensive therapy for distal coronary embolization and abnormal myocardial perfusion related to percutaneous coronary interventions(CEMPAS)[J].FUJIAN MEDICAL JOURNAL,2021,43(02):27-30.
点击复制

他汀强化预处理对PCI介导CEMPAS的防治效果观察()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期数:
2021年02期
页码:
27-30
栏目:
临床研究
出版日期:
2021-04-15

文章信息/Info

Title:
Statin pretreatment and intensive therapy for distal coronary embolization and abnormal myocardial perfusion related to percutaneous coronary interventions(CEMPAS)
文章编号:
1002-2600(2021)02-0027-04
作者:
孙伏清; 林永芳; 周 密; 郭 城; 黄 奇; 林凯金; 陈 平
福建医科大学附属福清市医院 福建省福清市医院心血管内科(福清 350300)
Author(s):
SUN Fuqing;  LIN Yongfang;  ZHOU Mi;  GUO Cheng;  HUANG Qi;  LIN Kaijin;  CHEN Ping
Department of Cardiovascular,Fuqing Municipal Hospital, Fuqing Municipal Hospital Affiliated to Fujian Medical University,Fuqing,Fujian 350300,China
关键词:
他汀;  急性冠脉综合征;  经皮冠脉介入手术
Keywords:
statin;  acute coronary syndrome;  percutaneous coronary intervention
分类号:
R543.3; R540.46
文献标志码:
B
摘要:
目的 探讨他汀类药物强化预处理对经皮冠状动脉介入治疗(PCI)介导的相关性远端血管栓塞及心肌灌注障碍(CEMPAS)的防治效果。方法 选择212例具备PCI术指征的急性冠脉综合征(ACS)患者,男156例,女66例; 年龄(65±11)岁。随机分为两组:110例术前7 d服用阿托伐他汀40 mg/d强化治疗, 其余102例服用阿托伐他汀20 mg/d常规剂量治疗。分别测量PCI术前及PCI术后心肌梗死溶栓治疗(TIMI)血流水平及术后6 h肌钙蛋白I(TnI)、肌酸激酶同工酶(CK-MB)、高敏C反应蛋白(hs-CRP),并评估两组患者临床随访3个月的主要心血管事件。结果 两组患者的基线水平及血管造影的特征具有可比性。PCI术前两组患者的TnI 、CK-MB 和 hs-CRP 水平无差异; PCI术后TnI、CK-MB和hs-CRP水平均增加。他汀强化治疗组患者与常规剂量他汀治疗组比较,PCI术后即刻3级血流发生率[(99.5±5.2)% vs(96.7±5.0)%,P<0.05]较高,术后6 h TnI、CK-MB、hs-CRP水平[(0.36±0.12)vs(1.33±0.47)ng/mL, P<0.01;(14.2±5.78)vs(47.3±16.4)IU/L, P<0.05;(6.42±3.56)vs(8.23±3.67)mg/L, P<0.05]及随访3个月的主要心血管事件发生率(0.9% vs 2.9%, P<0.05; 0.9% vs 3.9%, P<0.05; 0.9% vs 2.9%, P<0.05)均明显降低。结论 该研究表明ACS患者实施阿托伐他汀强化预处理具有改善PCI介导的CEMPAS的防治效果。
Abstract:
Objective This study sought to investigate potential protective effects of atorvastatin in patients with CEMPAS undergoing percutaneous coronary intervention(PCI).Methods A total of 212 ACS patients [156 males and 66 females, aged(65±11)years] with PCI indications were randomly divided into two groups: 110 cases were taken seven days before PCI with atorvastatin 40 mg/day intensive treatment,and the remaining 102 patients were treated with regular doses of atorvastatin 20 mg/day. The thrombolysis in myocardial infarction(TIMI)blood flow levels before and after PCI, and TnI, CK-MB, and hs-CRP six hours after operation weremeasured, and the major cardiovascular events within three months of clinical follow-up in both groups were assessed.Results Baseline clinical and angiographic characteristics of the two groups of patients were comparable.There were no differences in TnI, CK-MB and hs-CRP levels between the two groups of patients before PCI.TnI, CK-MB and hs-CRP levels increased after PCI.Patients in the statin intensive treatment group had slow blood flow or no regurgitation immediately after PCI.The levels of TnI, CK-MB, and hs-CRP at six hours after surgery were followed.Compared with maintaining regular doses of statin group, the major cardiovascular events during the 3-month follow-up period were significantly reduced.Conclusion The study shows that intensive atorvastatin pretreatment in patients with ACS can improve the prevention and treatment of PCI-mediated CEMPAS.

参考文献/References:

[1] Selvanayagam J B,Cheng A S,Jerosch-Herold M,et al.Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study[J].Circulation,2007,116(13):1458-1464.
[2] Hoon K Y,Ae-Young H,Ho J M,et al.A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents[J]. Atherosclerosis,2019,289:109-117.
[3]Taqueti V R,Ridker P M.Lipid-Lowering and antiinflammatory benefits of statin therapy: More than meets the plaque[J].Circ Cardiovasc Imaging,2017,10(7):112-119.
[4] Wongsalap Y,Jedsadayanmata A.Trends and predictors of high-intensity statin therapy and LDL-C goal achievement among Thai patients with acute coronary syndrome[J]. J Cardiol,2020,75(3):275-281.
[5] Wakana N,Tsubata H,Zen K.A case report: Near-infrared spectroscope ultrasonography can detect the plaque stabilization of non-culprit lesion in acs patients by the combination therapy of Pcsk9 inhibitor and statin[J]. Journal of the American College of Cardiology,2019,73(9):123-129.
[6]Xiao Y,He S Y,Zhang Z W,et al.Effect of high-dose statin pretreatment for myocardial perfusion in patients receiving percutaneous coronary intervention(PCI): a Meta-analysis of 15 randomized studies.[J]. Medical Science Monitor,2018,24(3):9166-9176.
[7] Mitsuaki S,Shun M,Takayuki A,et al.Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry[J]. PloS one,2017,24(3):1112-1118.
[8] Nakamura D,Shimamura K,Capodanno D,et al.Fate of nonculprit plaques in patients with STEMI undergoing primary PCI followed by statin therapy[J]. JACC: Cardiovascular Imaging,2017,10(7):827-829.
[9] Theodoropoulos K,Meelu O A,Mennuni M,et al.CRT-100.06 Differences in quantitative coronary angiographic(QCA)characteristics of coronary artery disease and clinical outcomes between statin pre-treated and statin-Naïve human immunodeficiency virus(HIV)patients undergoing percutaneous coronary intervention(PCI)[J]. JACC: Cardiovascular Interventions,2017,10(3):620-627.
[10] Sawano M,Kohsaka S,Abe T,et al.Patterns of statin non-prescription in patients with established coronary artery disease:A report from a contemporary multicenter Japanese PCI registry[J].PLOS ONE,2017,12(8):82-87.

更新日期/Last Update: 2021-04-15